Roche has announced the launch of Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody or PRAME Antibody to identify PRAME protein expression in tissue samples from patients with suspected melanoma.

Because the PRAME (PReferentially expressed Antigen in MElanoma) protein is expressed in most melanomas, the PRAME Antibody* is used as an aid to differentiate between benign and malignant lesions to help improve diagnostic decisions. If PRAME expression is detected, this suggests that the lesion is malignant.

About PRAME Antibody

The antibody is fully automated on the full line of Roche BenchMark IHC/ISH instruments. This antibody is validated for use using OptiView DAB IHC Detection, ultraView Universal DAB Detection and ultraView Universal Alkaline Phosphatase Red Detection Kits, giving added flexibility to laboratories and pathologists’ preferences.

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into one of the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. As a self-described pioneer in personalized healthcare, the company says it wants to further transform how healthcare is delivered to have an even greater impact.

*Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody


  1. American Cancer Society.
  2. Lezcano, C. et al. PRAME expression in melanocytic tumors. Am J Surg Pathol 2018;42(11):1456-1465.
  3. Lezcano, C. et al. PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions. Surg Pathol Clin 2021 Jun;14(2):165-175
  4. Lezcano, C. et al. Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma. Am J Surg Pathol 2020;44(4):503-508.